CN1125812C - 2－氨基－4－(4－氟苄基氨基)－1－乙氧基羰基氨基苯的新变体及其制备方法 - Google Patents

2－氨基－4－(4－氟苄基氨基)－1－乙氧基羰基氨基苯的新变体及其制备方法 Download PDF

Info

Publication number
CN1125812C
CN1125812C CN98801733A CN98801733A CN1125812C CN 1125812 C CN1125812 C CN 1125812C CN 98801733 A CN98801733 A CN 98801733A CN 98801733 A CN98801733 A CN 98801733A CN 1125812 C CN1125812 C CN 1125812C
Authority
CN
China
Prior art keywords
modification
compound
preparation
variant
variants
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
CN98801733A
Other languages
English (en)
Chinese (zh)
Other versions
CN1243506A (zh
Inventor
P·美塞尔
K－F·兰德拉夫
J·萨菲
W·瑟尔
M·里舍
A·奥布里克
B·库茨彻
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hector Searl Pharmaceutical Co
Valente Pharmaceuticals North America Inc
Original Assignee
Viatris GmbH and Co KG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Viatris GmbH and Co KG filed Critical Viatris GmbH and Co KG
Publication of CN1243506A publication Critical patent/CN1243506A/zh
Application granted granted Critical
Publication of CN1125812C publication Critical patent/CN1125812C/zh
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
    • C07C271/26—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atom of at least one of the carbamate groups bound to a carbon atom of a six-membered aromatic ring
    • C07C271/28—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atom of at least one of the carbamate groups bound to a carbon atom of a six-membered aromatic ring to a carbon atom of a non-condensed six-membered aromatic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pain & Pain Management (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
CN98801733A 1997-01-20 1998-01-09 2－氨基－4－(4－氟苄基氨基)－1－乙氧基羰基氨基苯的新变体及其制备方法 Expired - Lifetime CN1125812C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19701694.4 1997-01-20
DE19701694A DE19701694A1 (de) 1997-01-20 1997-01-20 Neue Modifikationen des 2-Amino-4-(4-fluorbenzylamino)-l-ethoxycarbonyl-aminobenzen sowie Verfahren zu ihrer Herstellung

Publications (2)

Publication Number Publication Date
CN1243506A CN1243506A (zh) 2000-02-02
CN1125812C true CN1125812C (zh) 2003-10-29

Family

ID=7817756

Family Applications (1)

Application Number Title Priority Date Filing Date
CN98801733A Expired - Lifetime CN1125812C (zh) 1997-01-20 1998-01-09 2－氨基－4－(4－氟苄基氨基)－1－乙氧基羰基氨基苯的新变体及其制备方法

Country Status (30)

Country Link
US (2) US5914425A (enExample)
EP (1) EP0956281B1 (enExample)
JP (1) JP4138886B2 (enExample)
CN (1) CN1125812C (enExample)
AR (1) AR015349A1 (enExample)
AT (1) ATE222235T1 (enExample)
AU (1) AU730776B2 (enExample)
BG (1) BG63893B1 (enExample)
BR (1) BR9806784A (enExample)
CA (3) CA2278201C (enExample)
CZ (1) CZ301778B6 (enExample)
DE (2) DE19701694A1 (enExample)
DK (1) DK0956281T3 (enExample)
EG (1) EG21239A (enExample)
ES (1) ES2178152T3 (enExample)
HU (1) HU227625B1 (enExample)
ID (1) ID22645A (enExample)
IL (1) IL130384A (enExample)
IS (1) IS2115B (enExample)
NO (2) NO311642B1 (enExample)
NZ (1) NZ336205A (enExample)
PL (1) PL195956B1 (enExample)
PT (1) PT956281E (enExample)
RU (1) RU2186765C2 (enExample)
SK (1) SK285303B6 (enExample)
TR (1) TR199901674T2 (enExample)
TW (1) TW531527B (enExample)
UA (1) UA63937C2 (enExample)
WO (1) WO1998031663A1 (enExample)
ZA (1) ZA98319B (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102531966A (zh) * 2011-12-23 2012-07-04 山东创新药物研发有限公司 瑞替加滨的新晶型d及其制备方法

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6348486B1 (en) 2000-10-17 2002-02-19 American Home Products Corporation Methods for modulating bladder function
US6589986B2 (en) 2000-12-20 2003-07-08 Wyeth Methods of treating anxiety disorders
AR033095A1 (es) * 2001-04-04 2003-12-03 Wyeth Corp Metodos para el tratamiento de motilidad gastrica hiperactiva
US20050089559A1 (en) * 2003-10-23 2005-04-28 Istvan Szelenyi Combinations of potassium channel openers and sodium channel inhibitors or sodium channel-influencing active compounds for treating pains
US7960436B2 (en) * 2006-06-05 2011-06-14 Valeant Pharmaceuticals International Substituted arylamino-1,2,3,4-tetrahydro naphthalenes and-2,3-dihydro-1H-indenes as potassium channel modulators
US20080045534A1 (en) * 2006-08-18 2008-02-21 Valeant Pharmaceuticals North America Derivatives of 1,3-diamino benzene as potassium channel modulators
NZ575652A (en) * 2006-08-23 2011-08-26 Valeant Pharmaceuticals Int Derivatives of 4-(n-azacycloalkyl) anilides as potassium channel modulators
US8993593B2 (en) * 2006-08-23 2015-03-31 Valeant Pharmaceuticals International N-(4-(6-fluoro-3,4-dihydroisoquinolin-2(1H)-yl)-2,6-dimethylphenyl)-3,3-dimethylbutanamide as potassium channel modulators
US8722929B2 (en) * 2006-10-10 2014-05-13 Valeant Pharmaceuticals International N-[2-amino-4-(phenylmethoxy)phenyl] amides and related compounds as potassium channel modulators
BRPI0719590A2 (pt) * 2006-11-28 2014-01-21 Valeant Pharmaceuticals Int Análogos de retigabina 1,4 diamino bicíclica como modulares de canal de potássio
US8367684B2 (en) * 2007-06-13 2013-02-05 Valeant Pharmaceuticals International Derivatives of 4-(N-azacycloalkyl) anilides as potassium channel modulators
US8563566B2 (en) 2007-08-01 2013-10-22 Valeant Pharmaceuticals International Naphthyridine derivatives as potassium channel modulators
US7786146B2 (en) * 2007-08-13 2010-08-31 Valeant Pharmaceuticals International Derivatives of 5-amino-4,6-disubstituted indole and 5-amino-4,6-disubstituted indoline as potassium channel modulators
JP2011528666A (ja) * 2008-07-18 2011-11-24 バレアント プハルマセウトイカルス インターナショナル 放出調節製剤及びその使用方法
US20100323015A1 (en) * 2008-07-18 2010-12-23 Biljana Nadjsombati Modified release formulation and methods of use
US20100323016A1 (en) * 2008-07-18 2010-12-23 Biljana Nadjsombati Modified release formulation and methods of use
DE102009013612A1 (de) 2009-03-17 2010-09-23 Ratiopharm Gmbh Retigabin-Tabletten, bevorzugt mit modifizierter Freisetzung
DE102009013613A1 (de) 2009-03-17 2010-09-23 Ratiopharm Gmbh Trockenverarbeitung von Retigabin
DE102009013611A1 (de) 2009-03-17 2010-09-23 Ratiopharm Gmbh Festes Retigabin in nicht-kristalliner Form
WO2011039369A2 (en) 2009-10-02 2011-04-07 Medichem S.A. Amorphous forms of a 2-amino-4-(4-fluorobenzylamino)phenylcarbamate derivative
SG181827A1 (en) 2010-01-20 2012-07-30 Glaxo Group Ltd Novel retigabine composition
WO2011101456A2 (en) * 2010-02-19 2011-08-25 Medichem S.A. Stabilized phenylcarbamate derivative in solid state
CN202095728U (zh) 2010-10-29 2012-01-04 假日集团控股有限公司 行李箱把手
CN102464233A (zh) * 2010-11-18 2012-05-23 江苏邦威机械制造有限公司 一种卧式差速缠丝机用应力发生装置
JP2014510714A (ja) 2011-01-18 2014-05-01 グラクソ グループ リミテッド レチガビンの製造方法
CN102241608A (zh) * 2011-05-12 2011-11-16 天津市汉康医药生物技术有限公司 瑞替加滨化合物及其组合物
WO2013008250A2 (en) * 2011-07-01 2013-01-17 Dr.Reddys Laboratories Limited. Crystalline form of retigabine and processes for mixture of retigabine crystalline modifications
WO2013011518A1 (en) 2011-07-21 2013-01-24 Arch Pharmalabs Limited Process for the preparation of retigabine of the formula i and pharmaceutically acceptable salts thereof
USD696019S1 (en) 2011-10-21 2013-12-24 Travelpro International Inc. Handle for luggage
US20140350285A1 (en) * 2012-01-30 2014-11-27 Symed Labs Limited Novel polymorphs of n-[2-amino-4-(4-fluorobenzylamino)-phenyl] carbamic acid ethyl ester and processes thereof
CN103373941B (zh) * 2012-04-11 2016-08-17 浙江九洲药物科技有限公司 瑞替加滨及其中间体的制备方法
WO2013179298A2 (en) * 2012-04-23 2013-12-05 Cadila Healthcare Limited A process for preparation of phenyl carbamate derivative and polymorphic forms thereof
WO2014023270A1 (en) 2012-08-09 2014-02-13 Zentiva, K.S. Salts or co-crystals of ethyl n-[2-amino-4-[(4-fluorophenyl)methylamino]-phenyl]carbamate
CN102964273B (zh) * 2012-12-06 2014-04-02 北京英科博雅科技有限公司 瑞替加滨的新晶型f及其制备方法
USD773819S1 (en) 2015-05-27 2016-12-13 Travelpro Products, Inc. Handle for luggage
TWI886158B (zh) 2019-10-10 2025-06-11 加拿大商再諾製藥公司 選擇性鉀通道調節劑之固態晶型
JP2022553569A (ja) 2019-11-08 2022-12-23 ゼノン・ファーマシューティカルズ・インコーポレイテッド うつ病性障害の治療方法
WO2022173855A1 (en) 2021-02-09 2022-08-18 Xenon Pharmaceuticals Inc. Voltage-gated potassium channel opener for use in treating anhedonia

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3917113A1 (de) * 1989-05-26 1990-11-29 Schwarzkopf Gmbh Hans Verfahren zur selektiven herstellung von n(pfeil hoch)4(pfeil hoch)-substituierten 1,4-diamino-2-nitrobenzolen
GB8921792D0 (en) * 1989-09-27 1989-11-08 May & Baker Ltd New compositions of matter
DE4200259A1 (de) * 1992-01-08 1993-07-15 Asta Medica Ag Neue 1,2,4-triaminobenzol-derivate und verfahren zu deren herstellung

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102531966A (zh) * 2011-12-23 2012-07-04 山东创新药物研发有限公司 瑞替加滨的新晶型d及其制备方法
CN102531966B (zh) * 2011-12-23 2013-07-24 山东创新药物研发有限公司 瑞替加滨的晶型d及其制备方法

Also Published As

Publication number Publication date
ZA98319B (en) 1998-05-07
CA2278201C (en) 2009-06-16
US6538151B1 (en) 2003-03-25
US5914425A (en) 1999-06-22
DE19701694A1 (de) 1998-07-23
BG103657A (en) 2000-02-29
NO2011017I1 (no) 2011-09-26
ES2178152T3 (es) 2002-12-16
RU2186765C2 (ru) 2002-08-10
IL130384A (en) 2003-02-12
ATE222235T1 (de) 2002-08-15
DK0956281T3 (da) 2002-11-04
NO993452D0 (no) 1999-07-13
AR015349A1 (es) 2001-05-02
AU730776B2 (en) 2001-03-15
WO1998031663A1 (de) 1998-07-23
JP2001508077A (ja) 2001-06-19
IS5098A (is) 1999-06-29
PT956281E (pt) 2002-12-31
BG63893B1 (bg) 2003-05-30
HUP0000944A2 (hu) 2000-09-28
NZ336205A (en) 2000-01-28
CA2632585A1 (en) 1998-07-23
HUP0000944A3 (en) 2000-10-30
AU6208198A (en) 1998-08-07
NO2011017I2 (no) 2013-04-02
SK95699A3 (en) 2000-03-13
NO311642B1 (no) 2001-12-27
CA2634811A1 (en) 1998-07-23
BR9806784A (pt) 2000-05-02
HU227625B1 (en) 2011-09-28
NO993452L (no) 1999-07-13
CA2278201A1 (en) 1998-07-23
UA63937C2 (uk) 2004-02-16
EP0956281A1 (de) 1999-11-17
CA2634811C (en) 2012-11-20
ID22645A (id) 1999-12-02
JP4138886B2 (ja) 2008-08-27
EP0956281B1 (de) 2002-08-14
IS2115B (is) 2006-06-15
IL130384A0 (en) 2000-06-01
SK285303B6 (sk) 2006-10-05
PL335647A1 (en) 2000-05-08
CN1243506A (zh) 2000-02-02
EG21239A (en) 2001-03-31
TR199901674T2 (enExample) 1999-10-21
PL195956B1 (pl) 2007-11-30
CZ250899A3 (cs) 1999-11-17
CZ301778B6 (cs) 2010-06-23
CA2632585C (en) 2010-08-24
HK1024230A1 (en) 2000-10-05
TW531527B (en) 2003-05-11
DE59805186D1 (de) 2002-09-19

Similar Documents

Publication Publication Date Title
CN1125812C (zh) 2－氨基－4－(4－氟苄基氨基)－1－乙氧基羰基氨基苯的新变体及其制备方法
EP2016045B1 (en) A tigecycline crystalline form and processes for its preparation
CN1406238A (zh) N－[4－[2－(2－氨基－4，7－二氢－4－氧代－3H－吡咯并[2，3－d]嘧啶－5－基)乙基]苯甲酰基]－L－谷氨酸的一种新晶形及其制备方法
CA3195789A1 (en) Solid state forms of resmetirom
CN1612859A (zh) 结晶[R－(R*，R*)]－2－(4－氟苯基)－β,δ－二羟基－5－(1－甲基乙基)－3－苯基－4－[(苯基氨基)羰基]-1H-吡咯-庚酸钙盐(2∶1)
KR20090082399A (ko) 벤조티오펜 화합물의 결정형 및 그의 제조방법
EP4482836A1 (en) Solid state forms of gusacitinib
US20040063782A1 (en) Bicalutamide forms
JP6908657B2 (ja) ４−［２−ジメチルアミノ−１−（１−ヒドロキシシクロヘキシル）エチル］フェニル４−メチルベンゾエートヒドロクロリドの多形体、それらを作製する方法及びそれらの使用
KR102544543B1 (ko) L,d-엘도스테인의 개별적 공결정화물
TWI656116B (zh) Crystal form of 9-aminomethyl substituted tetracycline compound and preparation method thereof
WO2023199258A1 (en) Solid state forms of mavacamten and process for preparation thereof
HK1024230B (en) Novel modifications to 2-amino-4-(4-fluorobenzylamino)-1-ethoxycai and processes for preparing said compound
KR20200127480A (ko) 테네리글립틴 에디실산염 결정형 및 이의 제조방법
WO2025191534A1 (en) Solid state forms of zasocitinib and process for preparation thereof
WO2024180474A1 (en) Solid state forms of sabizabulin and process for preparation thereof
AU2024229006A1 (en) Crystal form of 8-chloro-3-pentyl-3,7-dihydro-1h-purin-2,6-dione compound and preparation method therefor
CN1151403A (zh) 哌啶衍生物晶体、其制备所用的中间体以及其制备方法
HK1227882B (zh) 一种钠-葡萄糖协同转运蛋白2抑制剂的l-脯氨酸复合物、其一水合物及晶体

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
ASS Succession or assignment of patent right

Owner name: EKSEL PHARMACEUTICAL COMPANY

Free format text: FORMER OWNER: VIATELESS LIMITED PARTNERSHIP

Effective date: 20050930

C41 Transfer of patent application or patent right or utility model
C56 Change in the name or address of the patentee

Owner name: VALENTIAN MEDICINE NORTH AMERICA CO.,LTD.

Free format text: FORMER NAME OR ADDRESS: EKSEL PHARMACEUTICAL COMPANY

CP01 Change in the name or title of a patent holder

Address after: American California

Patentee after: Valente pharmaceuticals North America Inc.

Address before: American California

Patentee before: Hector Searl pharmaceutical Co.

TR01 Transfer of patent right

Effective date of registration: 20050930

Address after: American California

Patentee after: Hector Searl pharmaceutical Co.

Address before: German Homburg

Patentee before: Viatris GmbH & Co.kg

CX01 Expiry of patent term

Granted publication date: 20031029

CX01 Expiry of patent term